CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.44
10.56%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.10
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

NextCure Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.61
Open* 1.47
1-Year Change* 2.8%
Day's Range* 1.42 - 1.55
52 wk Range 0.98-1.92
Average Volume (10 days) 45.07K
Average Volume (3 months) 1.99M
Market Cap 32.09M
P/E Ratio -100.00K
Shares Outstanding 27.90M
Revenue N/A
EPS -2.36
Dividend (Yield %) N/A
Beta 0.25
Next Earnings Date Feb 29, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 22, 2024 1.44 -0.03 -2.04% 1.47 1.55 1.42
Feb 21, 2024 1.61 0.15 10.27% 1.46 1.61 1.46
Feb 20, 2024 1.53 0.12 8.51% 1.41 1.53 1.39
Feb 16, 2024 1.43 0.06 4.38% 1.37 1.43 1.31
Feb 15, 2024 1.38 0.01 0.73% 1.37 1.39 1.32
Feb 14, 2024 1.38 0.09 6.98% 1.29 1.38 1.28
Feb 13, 2024 1.30 -0.01 -0.76% 1.31 1.33 1.29
Feb 12, 2024 1.36 0.01 0.74% 1.35 1.38 1.30
Feb 9, 2024 1.33 0.08 6.40% 1.25 1.34 1.25
Feb 8, 2024 1.27 -0.01 -0.78% 1.28 1.29 1.24
Feb 7, 2024 1.28 -0.02 -1.54% 1.30 1.31 1.28
Feb 6, 2024 1.32 0.06 4.76% 1.26 1.34 1.22
Feb 5, 2024 1.26 0.05 4.13% 1.21 1.31 1.21
Feb 2, 2024 1.21 -0.02 -1.63% 1.23 1.24 1.19
Feb 1, 2024 1.25 0.08 6.84% 1.17 1.30 1.17
Jan 31, 2024 1.20 0.06 5.26% 1.14 1.22 1.13
Jan 30, 2024 1.14 -0.01 -0.87% 1.15 1.15 1.13
Jan 29, 2024 1.16 -0.06 -4.92% 1.22 1.25 1.14
Jan 26, 2024 1.21 0.04 3.42% 1.17 1.27 1.17
Jan 25, 2024 1.17 0.03 2.63% 1.14 1.21 1.14

NextCure, Inc. Events

Time (UTC) Country Event
Thursday, February 29, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 NextCure Inc Earnings Release
Q4 2023 NextCure Inc Earnings Release

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 NextCure Inc Earnings Release
Q1 2024 NextCure Inc Earnings Release

Forecast

-

Previous

-
Friday, June 21, 2024

Time (UTC)

14:00

Country

US

Event

NextCure Inc Annual Shareholders Meeting
NextCure Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 22.378 6.347 0
Total Operating Expense 75.909 70.765 63.603 43.829 23.196
Selling/General/Admin. Expenses, Total 21.71 20.573 17.049 9.613 3.409
Research & Development 54.199 50.192 46.554 34.216 19.787
Operating Income -75.909 -70.765 -41.225 -37.482 -23.196
Interest Income (Expense), Net Non-Operating 1.176 1.376 4.622 3.745 0.397
Net Income Before Taxes -74.733 -69.389 -36.603 -33.737 -22.799
Net Income After Taxes -74.733 -69.389 -36.603 -33.737 -22.799
Net Income Before Extra. Items -74.733 -69.389 -36.603 -33.737 -22.799
Net Income -74.733 -69.389 -36.603 -33.737 -22.799
Income Available to Common Excl. Extra. Items -74.733 -69.389 -36.603 -33.737 -22.799
Income Available to Common Incl. Extra. Items -74.733 -69.389 -36.603 -33.737 -22.799
Diluted Net Income -74.733 -69.389 -36.603 -33.737 -22.799
Diluted Weighted Average Shares 27.7442 27.616 27.5322 15.6955 21.9354
Diluted EPS Excluding Extraordinary Items -2.69364 -2.51264 -1.32946 -2.14947 -1.03937
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.69364 -2.51264 -1.32946 -2.14947 -1.03937
Revenue 0 22.378 6.347
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue
Total Operating Expense 19.158 17.071 17.771 19.239 18.128
Selling/General/Admin. Expenses, Total 5.711 5.424 4.949 5.711 5.303
Research & Development 13.447 11.647 12.822 13.528 12.825
Operating Income -19.158 -17.071 -17.771 -19.239 -18.128
Interest Income (Expense), Net Non-Operating 1.299 0.975 0.471 0.328 0.208
Net Income Before Taxes -17.859 -16.096 -17.3 -18.911 -17.92
Net Income After Taxes -17.859 -16.096 -17.3 -18.911 -17.92
Net Income Before Extra. Items -17.859 -16.096 -17.3 -18.911 -17.92
Net Income -17.859 -16.096 -17.3 -18.911 -17.92
Income Available to Common Excl. Extra. Items -17.859 -16.096 -17.3 -18.911 -17.92
Income Available to Common Incl. Extra. Items -17.859 -16.096 -17.3 -18.911 -17.92
Diluted Net Income -17.859 -16.096 -17.3 -18.911 -17.92
Diluted Weighted Average Shares 27.8287 27.7745 27.774 27.7488 27.7448
Diluted EPS Excluding Extraordinary Items -0.64175 -0.57952 -0.62288 -0.68151 -0.64589
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.64175 -0.57952 -0.62288 -0.68151 -0.64589
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 163.983 227.817 287.978 339.995 135.785
Cash and Short Term Investments 159.911 219.591 283.448 334.605 135.173
Cash & Equivalents 26.63 12.337 32.772 34.091 135.173
Prepaid Expenses 4.072 8.187 2.824 3.684 0.152
Other Current Assets, Total 0.039 1.706 1.706 0.46
Total Assets 184.161 242.386 306.644 356.168 147.628
Property/Plant/Equipment, Total - Net 16.913 13.992 15.809 12.09 11.407
Property/Plant/Equipment, Total - Gross 33.543 26.729 24.369 17.236 13.876
Accumulated Depreciation, Total -16.63 -12.737 -8.56 -5.146 -2.469
Other Long Term Assets, Total 3.265 0.577 2.857 4.083 0.436
Total Current Liabilities 9.127 6.608 10.325 15.042 10.298
Accounts Payable 4.27 1.942 3.901 1.861 2.483
Accrued Expenses 4.857 4.449 4.627 4.871 2.411
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 1.667 1.667 0.387
Other Current Liabilities, Total 0.217 0.13 6.643 5.017
Total Liabilities 16.631 9 12.923 34.684 32.349
Total Long Term Debt 0 0 1.806 3.333 0.073
Long Term Debt 0 1.806 3.333 0.073
Other Liabilities, Total 7.504 2.392 0.792 16.309 21.978
Total Equity 167.53 233.386 293.721 321.484 115.279
Preferred Stock - Non Redeemable, Net 0 162.223
Common Stock 0.028 0.028 0.028 0.027 0.011
Additional Paid-In Capital 430.755 421.047 410.551 402.529 0.342
Retained Earnings (Accumulated Deficit) -261.759 -187.026 -117.637 -81.034 -47.297
Total Liabilities & Shareholders’ Equity 184.161 242.386 306.644 356.168 147.628
Total Common Shares Outstanding 27.7745 27.681 27.5688 27.4993 21.9354
Short Term Investments 133.281 207.254 250.676 300.514
Other Equity, Total -1.494 -0.663 0.779 -0.038
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 122.684 135.299 148.918 163.983 175.315
Cash and Short Term Investments 118.206 130.623 145.493 159.911 169.214
Cash & Equivalents 19.519 22.019 29.973 26.63 31.05
Short Term Investments 98.687 108.604 115.52 133.281 138.164
Prepaid Expenses 4.478 4.676 3.425 4.072 6.062
Other Current Assets, Total 0.039
Total Assets 139.939 153.38 167.791 184.161 189.909
Property/Plant/Equipment, Total - Net 14.401 15.223 16.05 16.913 12.125
Other Long Term Assets, Total 2.854 2.858 2.823 3.265 2.469
Total Current Liabilities 6.552 7.82 6.266 9.127 5.891
Accounts Payable 2.602 2.813 1.919 4.27 1.846
Accrued Expenses 3.95 5.007 4.347 4.857 3.943
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0
Other Current Liabilities, Total 0.102
Total Liabilities 13.487 14.95 13.588 16.631 8.368
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 6.935 7.13 7.322 7.504 2.477
Total Equity 126.452 138.43 154.203 167.53 181.541
Common Stock 0.028 0.028 0.028 0.028 0.028
Additional Paid-In Capital 437.042 435.041 432.833 430.755 428.368
Retained Earnings (Accumulated Deficit) -310.015 -295.714 -277.855 -261.759 -244.459
Other Equity, Total -0.603 -0.925 -0.803 -1.494 -2.396
Total Liabilities & Shareholders’ Equity 139.939 153.38 167.791 184.161 189.909
Total Common Shares Outstanding 27.84 27.84 27.7745 27.7745 27.7488
Property/Plant/Equipment, Total - Gross 33.543
Accumulated Depreciation, Total -16.63
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -74.733 -69.389 -36.603 -33.737 -22.799
Cash From Operating Activities -53.886 -57.283 -44.954 -35.623 7.992
Cash From Operating Activities 4.124 4.177 3.413 2.688 1.677
Non-Cash Items 9.951 10.288 7.911 1.886 0.263
Cash Taxes Paid 0
Cash Interest Paid 0.09 0.162 0.13 0.191 0.025
Changes in Working Capital 6.772 -2.359 -19.675 -6.46 28.851
Cash From Investing Activities 67.979 36.601 43.523 -303.923 -3.063
Capital Expenditures -2.116 -2.36 -7.132 -3.371 -3.063
Cash From Financing Activities 0.2 -3.265 -1.415 243.043 121.417
Financing Cash Flow Items -0.41
Issuance (Retirement) of Stock, Net 0.2 0.208 0.112 238.503 122.227
Issuance (Retirement) of Debt, Net 0 -3.473 -1.527 4.54 -0.4
Net Change in Cash 14.293 -23.947 -2.846 -96.503 126.346
Other Investing Cash Flow Items, Total 70.095 38.961 50.655 -300.552
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.096 -74.733 -57.433 -38.522 -20.602
Cash From Operating Activities -14.779 -53.886 -44.937 -29.936 -15.447
Cash From Operating Activities 0.96 4.124 3.117 2.096 2.097
Non-Cash Items 2.228 9.951 7.182 4.87 2.628
Cash Interest Paid 0.021 0.09 0.068 0.046 0.023
Changes in Working Capital -1.871 6.772 2.197 1.62 0.43
Cash From Investing Activities 18.122 67.979 63.511 45.623 13.702
Capital Expenditures -0.248 -2.116 -1.251 -0.719 -0.305
Other Investing Cash Flow Items, Total 18.37 70.095 64.762 46.342 14.007
Cash From Financing Activities 0 0.2 0.139 0.139 0.06
Issuance (Retirement) of Stock, Net 0 0.2 0.139 0.139 0.06
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash 3.343 14.293 18.713 15.826 -1.685
Cash Taxes Paid
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 9.7378 2711013 0 2023-06-30 LOW
Sofinnova Investments, Inc Venture Capital 9.5972 2671856 0 2023-06-30 HIGH
Pfizer Inc Corporation 7.0789 1970759 0 2023-04-24 LOW
Millennium Management LLC Hedge Fund 5.0613 1409055 -44965 2023-06-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.2632 908473 0 2023-06-30 LOW
Long Focus Capital Management LLC Hedge Fund 1.9975 556105 0 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.8435 513241 3602 2023-06-30 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.7545 488440 0 2023-06-30 MED
Tang Capital Management, LLC Hedge Fund 1.4368 400000 0 2023-06-30 MED
Richman (Michael S) Individual Investor 1.4236 396325 7133 2023-04-24 LOW
Citadel Advisors LLC Hedge Fund 1.4126 393263 -86584 2023-06-30 LOW
Federated MDTA LLC Investment Advisor/Hedge Fund 1.3181 366949 -21620 2023-06-30 HIGH
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.2341 343572 -3632 2023-06-30 LOW
BML Capital Management LLC Investment Advisor 1.1008 306465 0 2023-09-30 HIGH
Acuitas Investments LLC Investment Advisor/Hedge Fund 1.0302 286817 -17 2023-09-30 HIGH
Cardiff Park Advisors, LLC Investment Advisor 0.9411 262000 262000 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.8879 247200 2700 2023-06-30 HIGH
Dafna Capital Management, LLC Hedge Fund 0.6742 187696 0 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.6284 174934 -30284 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.566 157582 -10921 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

NextCure, Inc. Company profile

About NextCure Inc

Nextcure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its product candidates include NC318, NC410, and NC762. Its lead product candidate NC318, is an immunomedicine targeting an immunomodulatory receptor called Siglec-15 (S15). The Company is evaluating NC318 for the treatment of metastatic solid tumors, including head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC). It is conducting Phase II investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Its second product candidate NC410, is an immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor1. Its NC762, is a monoclonal antibody targeting an immunomodulatory molecule called human B7 homolog 4 protein (B7-H4).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, NextCure Inc revenues decreased from $22.4M to $0K. Net loss increased 90% to $69.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income, net decrease of 70% to $1.4M (income), Research and development - Balancing val increase of 6% to $46.1M (expense).

Industry: Bio Therapeutic Drugs

9000 Virginia Manor Rd Ste 200
BELTSVILLE
MARYLAND 20705-4214
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.54 Price
-2.410% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

50,973.45 Price
-1.460% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

77.40 Price
-1.130% 1D Chg, %
Long position overnight fee 0.0162%
Short position overnight fee -0.0381%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,972.10 Price
-0.050% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading